192 related articles for article (PubMed ID: 33618274)
21. Evaluation of a carbapenem antimicrobial stewardship program and clinical outcomes in a Japanese hospital.
Komatsu T; Inagaki R; Azuma S; Mochida S; Sato Y; Seto Y; Nihonyanagi S; Hoshiyama T; Wada T; Takayama Y; Atsuda K
J Infect Chemother; 2022 Jul; 28(7):884-889. PubMed ID: 35331613
[TBL] [Abstract][Full Text] [Related]
22. Piperacillin/tazobactam versus carbapenems in patients with severe bacterial infections: A systematic review with meta-analysis.
Munch MW; Granholm A; Jonsson AB; Sjövall F; Helleberg M; Hertz FB; Andersen JS; Steensen M; Achiam MP; Perner A; Møller MH
Acta Anaesthesiol Scand; 2023 Aug; 67(7):853-868. PubMed ID: 36919866
[TBL] [Abstract][Full Text] [Related]
23. Treatment efficacy and superinfection rates in complicated urinarytract infections treated with ertapenem or piperacillin tazobactam.
Dizbay M; Özger HS; Karaşahin Ö; Karaşahin EF
Turk J Med Sci; 2016 Dec; 46(6):1760-1764. PubMed ID: 28081324
[TBL] [Abstract][Full Text] [Related]
24. Ceftriaxone versus tazobactam/piperacillin and carbapenems in the treatment of aspiration pneumonia: A propensity score matching analysis.
Asai N; Suematsu H; Ohashi W; Shibata Y; Sakanashi D; Kato H; Shiota A; Watanabe H; Hagihara M; Koizumi Y; Yamagishi Y; Mikamo H
J Infect Chemother; 2021 Oct; 27(10):1465-1470. PubMed ID: 34158237
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of Carbapenems Compared With Noncarbapenem Broad-Spectrum Beta-Lactam Antibiotics as Initial Antibiotic Therapy Against Sepsis: A Nationwide Observational Study.
Umemura Y; Yamakawa K; Tanaka Y; Yoshimura J; Ogura H; Fujimi S
Crit Care Med; 2023 Sep; 51(9):1210-1221. PubMed ID: 37232855
[TBL] [Abstract][Full Text] [Related]
26. Comparative effectiveness of cefmetazole versus carbapenems and piperacillin/tazobactam as initial therapy for bacteremic acute cholangitis: A retrospective study.
Aoto K; Inose R; Kosaka T; Shikata K; Muraki Y
J Infect Chemother; 2024 Mar; 30(3):213-218. PubMed ID: 37832824
[TBL] [Abstract][Full Text] [Related]
27. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
Tamma PD; Han JH; Rock C; Harris AD; Lautenbach E; Hsu AJ; Avdic E; Cosgrove SE;
Clin Infect Dis; 2015 May; 60(9):1319-25. PubMed ID: 25586681
[TBL] [Abstract][Full Text] [Related]
28. Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies.
Yildirim I; Aytac S; Ceyhan M; Cetin M; Tuncer M; Cengiz AB; Secmeer G; Yetgin S
Pediatr Hematol Oncol; 2008 Jun; 25(4):291-9. PubMed ID: 18484473
[TBL] [Abstract][Full Text] [Related]
29. The Relationship of Comorbid Diseases and Empirical Antibiotic Usage with Superinfection in COVID-19 Patients.
Orak F; Nazik S; Yalcinkaya KT; Aral M; Ates S; Doganer A
J Coll Physicians Surg Pak; 2023 Aug; 33(8):852-856. PubMed ID: 37553921
[TBL] [Abstract][Full Text] [Related]
30. Comparison of Duration and Empiric Antibiotic Choice of Post-Operative Treatment in Abdominal Sepsis.
Surat G; Meyer-Sautter P; Rüsch J; Braun-Feldweg J; Germer CT; Lock JF
Surg Infect (Larchmt); 2022 Jun; 23(5):444-450. PubMed ID: 35532964
[No Abstract] [Full Text] [Related]
31. Carbapenems versus other beta-lactams in the treatment of hospitalised patients with infection: a mixed treatment comparison.
Edwards SJ; Clarke MJ; Wordsworth S; Welton NJ
Curr Med Res Opin; 2009 Jan; 25(1):251-61. PubMed ID: 19210156
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the Nephrotoxicity of Vancomycin in Combination With Cefepime, Meropenem, or Piperacillin/Tazobactam: A Prospective, Multicenter Study.
Mullins BP; Kramer CJ; Bartel BJ; Catlin JS; Gilder RE
Ann Pharmacother; 2018 Jul; 52(7):639-644. PubMed ID: 29442542
[TBL] [Abstract][Full Text] [Related]
33. Sustaining Antimicrobial Stewardship in a High-Antibiotic Resistance Setting.
Ng TM; Heng ST; Chua BH; Ang LW; Tan SH; Tay HL; Yap MY; Quek J; Teng CB; Young BE; Lin R; Ang B; Lee TH; Lye DC
JAMA Netw Open; 2022 May; 5(5):e2210180. PubMed ID: 35503216
[TBL] [Abstract][Full Text] [Related]
34. [Analysis of related factors of carbapenem resistant Klebsiella pneumoniae infection in patients with artificial airway].
Bian W; Chen W; Gu X; Wang S; Liu Y; Zhao G; Qin Y
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Nov; 32(11):1324-1330. PubMed ID: 33463491
[TBL] [Abstract][Full Text] [Related]
35. A change for the antibacterial treatment policy to decrease carbapenem consumption at a haematopoietic stem cell transplantation centre.
Metan G; Kaynar L; Yozgat N; Elmali F; Kürkçüoglu CA; Alp E; Çetin M
Infez Med; 2017 Mar; 25(1):33-37. PubMed ID: 28353453
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of a risk-guided strategy for empirical carbapenem use in febrile neutropenia.
Khoo AL; Zhao YJ; Teng M; Ying D; Jin J; Chee YL; Poon LM; Lim SE; Koh LP; Chng WJ; Lim BP; Hsu LY; Chai LYA
Int J Antimicrob Agents; 2018 Sep; 52(3):350-357. PubMed ID: 29751120
[TBL] [Abstract][Full Text] [Related]
37. [Risk of Acute Kidney Injury in Patients Treated with Vancomycin and Piperacillin/Tazobactam Compared to Vancomycin and Meropenem or Doripenem: A Retrospective Cohort Study].
Ide N; Sato S; Sawaguchi K
Yakugaku Zasshi; 2019; 139(12):1609-1614. PubMed ID: 31787651
[TBL] [Abstract][Full Text] [Related]
38. Comparing ceftolozane/tazobactam versus piperacillin/tazobactam as empiric therapy for complicated urinary tract infection in Taiwan: A cost-utility model focusing on gram-negative bacteria.
Chen GJ; Pan SC; Foo J; Morel C; Chen WT; Wang JT
J Microbiol Immunol Infect; 2019 Oct; 52(5):807-815. PubMed ID: 31029529
[TBL] [Abstract][Full Text] [Related]
39. Antimicrobial consumption in five adult intensive care units: a 33-month surveillance study.
Balkhy HH; El-Saed A; El-Metwally A; Arabi YM; Aljohany SM; Al Zaibag M; Baharoon S; Alothman AF
Antimicrob Resist Infect Control; 2018; 7():156. PubMed ID: 30598819
[TBL] [Abstract][Full Text] [Related]
40. Carbapenems versus Cephalosporin or Piperacillin-Tazobactam as Perioperative Antibiotic Prophylaxis in Liver Transplant Recipients with Model for End-Stage Liver Disease Scores of ≥30: A Retrospective Study in a Chinese Population.
Zhang W; Chen Y; Zhang Y; Wang R; Wang W; Bai X; Liang T
Infect Drug Resist; 2022; 15():4487-4494. PubMed ID: 35983301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
